KRAS and neoplasm: In order to ascertain the anti-tumor property of miR-422a is mediated by inhibition of BCL2L2 and KRAS, four siRNA specific for BCL2L2 (si-39, si-72, si-75, si-98) and KRAS (si-52, si-92, si-118, si-177) were generated using siRNA Selection software.